Phase I Study of Oral Azacitidine in Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Acute Myeloid Leukemia

PURPOSE: To determine the maximum-tolerated dose (MTD), safety, pharmacokinetic and pharmacodynamic profiles, and clinical activity of an oral formulation of azacitidine in patients with myelodysplastic syndromes (MDSs), chronic myelomonocytic leukemia (CMML), or acute myeloid leukemia (AML). PATIEN...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Garcia-Manero, Guillermo, Gore, Steven D., Cogle, Christopher, Ward, Renee, Shi, Tao, MacBeth, Kyle J., Laille, Eric, Giordano, Heidi, Sakoian, Sarah, Jabbour, Elias, Kantarjian, Hagop, Skikne, Barry
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2011
Assuntos:
Original Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3675699/
https://ncbi.nlm.nih.gov/pubmed/21576646
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2010.34.4226
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados